• 2025.09.11 (Thu)
  • All articles
  • LOGIN
  • JOIN
Global Economic Times
APEC2025KOREA가이드북
  • Synthesis
  • World
  • Business
  • Industry
  • ICT
  • Distribution Economy
  • Korean Wave News
  • Opinion
  • Arts&Culture
  • Sports
  • People & Life
  • Lee Yeon-sil Column
  • Ko Yong-chul Column
  • Photo News
  • New Book Guide
  • Cherry Garden Story
MENU
 
Home > Synthesis

Blood cancers: Lymphoma most common, multiple myeloma on the rise

Desk / Updated : 2025-02-22 07:53:55
  • -
  • +
  • Print

Lymphoma is the most common type of blood cancer, but multiple myeloma is rapidly increasing. Lymphoma is a tumor that develops in lymphocytes, a type of white blood cell, while multiple myeloma is a tumor that develops in the bone marrow. Unlike acute leukemia, lymphoma and multiple myeloma have stages. Myeloproliferative neoplasms can also develop into acute leukemia.

Lymphoma is the most common blood cancer

Lymphoma is divided into two main types: Hodgkin's lymphoma and non-Hodgkin's lymphoma. According to Professor Park Young-hoon of the Department of Hematology at Ewha Mokdong Hospital, Hodgkin's lymphoma is more common in people in their 20s, while non-Hodgkin's lymphoma is more common in people in their 50s. After the age of 60, Hodgkin's lymphoma increases again. Overall, non-Hodgkin's lymphoma accounts for about 95% of all cases, with the rest being Hodgkin's lymphoma.

Symptoms of lymphoma include swollen lymph nodes, especially in the jaw, clavicle, and groin. The swollen lymph nodes are usually painless and feel firm to the touch. Professor Park says that if you experience these symptoms along with weight loss and night sweats, you should suspect lymphoma.

Diagnosing lymphoma requires a comprehensive examination of the lymph node tissue. Therefore, it may be difficult to get an accurate diagnosis at a local clinic or small hospital. If you suspect lymphoma, it is best to get a thorough examination at a large hospital.

Treatment for lymphoma varies depending on the stage and type of lymphoma. In general, chemotherapy is used. However, if Hodgkin's lymphoma is confined to a very small area, radiation therapy may be used instead. When chemotherapy is used, high-dose chemotherapy drugs are used to kill even the smallest cancer cells. This can kill all the cells that make blood. For this reason, hematopoietic stem cells are extracted from the patient before chemotherapy and transplanted back after chemotherapy is completed.

Recently, CAR-T cell therapy, a so-called 4th generation treatment, is also being used in some cases. The complete remission rate for lymphoma is 70-80%. However, about 15% of patients experience a recurrence. The overall cure rate for lymphoma is 50-60%.

Multiple myeloma is increasing rapidly

Multiple myeloma is the fastest growing type of blood cancer in Korea. The cause is unknown, but it is thought to be related to genetic mutations and aging. Multiple myeloma develops over a long period of time. It can progress to multiple myeloma after an asymptomatic stage that shows no symptoms.

Multiple myeloma is a cancer that develops in plasma cells. Plasma cells are a type of white blood cell that is involved in the production of antibodies. When these plasma cells turn into cancer, abnormal antibodies are produced. These abnormal antibody덩어리 invade and melt the bones, causing fractures. They can also cause kidney failure and anemia.

Multiple myeloma is diagnosed through a bone marrow examination and other tests. Many patients are misdiagnosed with herniated discs or spinal stenosis and are later found to have multiple myeloma. Professor Park says that if an X-ray or MRI scan shows that the bones are melting, multiple myeloma may be suspected. The same is true if there is a compression fracture without severe osteoporosis. If you have anemia, proteinuria, poor kidney function, or back pain for no reason during a health checkup, you should be tested for multiple myeloma.

Treatment for multiple myeloma includes chemotherapy. In this case, as with lymphoma, autologous hematopoietic stem cell transplantation is often performed. However, if the patient's health is too poor or is over 70 years old, autologous hematopoietic stem cell transplantation is difficult, so only chemotherapy is performed.

Multiple myeloma is a difficult disease to cure. In the early 2000s, the survival rate was only 1-2%. Today, the survival rate is close to 50%. Professor Park says that relapses are frequent, so even if the patient is thought to be cured, they often have to be treated again. It is a disease that requires continuous monitoring.

Myeloproliferative neoplasms can be controlled with medication

Mutations in certain genes can cause hematopoietic stem cells to be produced abnormally. In this case, the number of red blood cells, white blood cells, and platelets increases, which is called myeloproliferative neoplasm. If abnormalities are found in a blood test, it is diagnosed through genetic mutation and bone marrow examination.

Myeloproliferative neoplasms are divided into four types: polycythemia vera, thrombocythemia, primary myelofibrosis, and chronic myelogenous leukemia. Symptoms and treatments vary depending on the type. Professor Lee Se-won of the Department of Hematology at Ewha Mokdong Hospital says that appropriate treatment can prevent the disease from worsening.

Symptoms of polycythemia vera include a red face. As the number of red blood cells increases, there is a risk of thrombosis and heart failure. To prevent this, low-dose aspirin is prescribed. Symptoms of thrombocythemia include frequent bruising. In this case, aspirin is prescribed to prevent thrombosis, or drugs are administered to control platelet levels.

In primary myelofibrosis, the bone marrow becomes fibrotic, and the function of making blood does not work properly. This causes anemia. The quality of life can be greatly reduced, as frequent blood transfusions are required. If the disease is left untreated, about 10% of patients develop acute myelogenous leukemia within 10 years. Professor Lee adds that with many good drugs available, primary myelofibrosis and chronic myelogenous leukemia can be prevented from developing into acute leukemia for life if properly managed. Currently, the survival rate for chronic myelogenous leukemia is over 90%.

[Copyright (c) Global Economic Times. All Rights Reserved.]

  • #globaleconomictimes
  • #글로벌이코노믹타임즈
  • #한국
  • #중기청
  • #재외동포청
  • #외교부
  • #micorea
  • #mykorea
  • #newsk
  • #nammidonganews
  • #singaporenewsk
Desk
Desk

Popular articles

  • Mitsubishi Pulls Out of Japanese Offshore Wind Projects Amid Soaring Costs

  • Burger King Fined ₩300 Million by Fair Trade Commission for Forcing Franchisees to Use Specific Cleaning Products and Tomatoes

  • Seiyoung Kim's Summer Surge Continues, Tied for Lead at FM Championship

I like it
Share
  • Facebook
  • X
  • Kakaotalk
  • LINE
  • BAND
  • NAVER
  • https://www.globaleconomictimes.kr/article/1065567091178546 Copy URL copied.
Comments >

Comments 0

Weekly Hot Issue

  • U.S. Expresses Regret Over Israeli Airstrike in Qatar, Backs Goal of Eliminating Hamas
  • Lim Young-woong's Seoul Concert Sells Out, Proving His Immense Ticket Power
  • Samsung's AI Prowess Dominates South Korea, but Lags on the Global Stage
  • Paraguayan Ambassador to US Claims China is Attempting to Interfere in Domestic Affairs
  • “The Judiciary, Public Prosecutor's Office, and Political Sphere Have Been Captured and Subordinated”
  • Paraguay's Anti-Money Laundering Efforts: Banking Sector Sees Surge in Suspicious Transactions in 2025

Most Viewed

1
Sexual Misconduct Controversy in the Cho Kuk Innovation Party: The Repeated Lack of Self-Purification in the Political Sphere
2
Mitsubishi Pulls Out of Japanese Offshore Wind Projects Amid Soaring Costs
3
Brazil Weighs Legal Action as U.S. Tariffs Escalate Trade Tensions
4
Jung Hoo Lee's Heroics Propel Giants to Walk-Off Victory
5
US Ends 'De Minimis' Exemption Permanently, No Exceptions for Any Country
광고문의
임시1
임시3
임시2

Hot Issue

Apple Unveils 'iPhone Air,' the Thinnest iPhone Ever, Starting at ₩1.59 Million in South Korea

Samsung's AI Prowess Dominates South Korea, but Lags on the Global Stage

An infant was injured by a stone thrown by a chimpanzee at a zoo in China, sparking concern among visitors.

AI Boom Fuels Memory Market Growth

China’s online public opinion manipulation goes beyond Korea

Global Economic Times
korocamia@naver.com
CEO : LEE YEON-SIL
Publisher : KO YONG-CHUL
Registration number : Seoul, A55681
Registration Date : 2024-10-24
Youth Protection Manager: KO YONG-CHUL
Singapore Headquarters
5A Woodlands Road #11-34 The Tennery. S'677728
Korean Branch
Phone : +82(0)10 4724 5264
#304, 6 Nonhyeon-ro 111-gil, Gangnam-gu, Seoul
Copyright © Global Economic Times All Rights Reserved
  • 에이펙2025
  • 우리방송
  • APEC2025가이드북TV
Search
Category
  • All articles
  • Synthesis
  • World
  • Business
  • Industry
  • ICT
  • Distribution Economy
  • Korean Wave News
  • Opinion
  • Arts&Culture
  • Sports
  • People & Life
  • Lee Yeon-sil Column
  • Ko Yong-chul Column
  • Photo News
  • New Book Guide
  • Cherry Garden Story
  • Multicultural News
  • Jobs & Workers
  • APEC 2025 KOREA GUIDE